Literature DB >> 24142110

Key intestinal genes involved in lipoprotein metabolism are downregulated in dyslipidemic men with insulin resistance.

Patrick Couture1, André J Tremblay, Isabelle Kelly, Valéry Lemelin, Arnaud Droit, Benoît Lamarche.   

Abstract

Insulin resistance (IR) is associated with elevated plasma levels of triglyceride-rich lipoproteins (TRLs) of intestinal origin. However, the mechanisms underlying the overaccumulation of apolipoprotein (apo)B-48-containing TRLs in individuals with IR are not yet fully understood. This study examined the relationships between apoB-48-containing TRL kinetics and the expression of key intestinal genes and proteins involved in lipid/lipoprotein metabolism in 14 obese nondiabetic men with IR compared with 10 insulin-sensitive (IS) men matched for waist circumference. The in vivo kinetics of TRL apoB-48 were assessed using a primed-constant infusion of L-[5,5,5-D₃]leucine for 12 h with the participants in a constantly fed state. The expression of key intestinal genes and proteins involved in lipid/lipoprotein metabolism was assessed by performing real-time PCR quantification and LC-MS/MS on duodenal biopsy specimens. The TRL apoB-48 pool size and production rate were 102% (P < 0.0001) and 87% (P = 0.01) greater, respectively, in the men with IR versus the IS men. On the other hand, intestinal mRNA levels of sterol regulatory element binding factor-2, hepatocyte nuclear factor-4α, and microsomal triglyceride transfer protein were significantly lower in the men with IR than in the IS men. These data indicate that IR is associated with intestinal overproduction of lipoproteins and significant downregulation of key intestinal genes involved in lipid/lipoprotein metabolism.

Entities:  

Keywords:  apolipoprotein B-100; apolipoprotein B-48; cholesterol; fatty acids; intestine; kinetic

Mesh:

Substances:

Year:  2013        PMID: 24142110      PMCID: PMC3927480          DOI: 10.1194/jlr.M040071

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  41 in total

Review 1.  Insulin resistance and cardiovascular disease.

Authors:  H N Ginsberg
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes.

Authors:  F K Welty; A H Lichtenstein; P H Barrett; G G Dolnikowski; E J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-12       Impact factor: 8.311

3.  Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study.

Authors:  J R McNamara; P K Shah; K Nakajima; L A Cupples; P W Wilson; J M Ordovas; E J Schaefer
Journal:  Atherosclerosis       Date:  2001-01       Impact factor: 5.162

4.  Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins.

Authors:  Kevin P Dwyer; P Hugh R Barrett; Dick Chan; Jock I Foo; Gerald F Watts; Kevin D Croft
Journal:  J Lipid Res       Date:  2002-02       Impact factor: 5.922

5.  Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.

Authors:  L Duvillard; F Pont; E Florentin; C Galland-Jos; P Gambert; B Vergès
Journal:  Eur J Clin Invest       Date:  2000-08       Impact factor: 4.686

6.  Cellular aspects of intestinal lipoprotein assembly in Psammomys obesus: a model of insulin resistance and type 2 diabetes.

Authors:  Monika Zoltowska; Ehud Ziv; Edgard Delvin; Daniel Sinnett; Ronny Kalman; Carole Garofalo; Ernest Seidman; Emile Levy
Journal:  Diabetes       Date:  2003-10       Impact factor: 9.461

7.  Short-term, high-fat diet increases the expression of key intestinal genes involved in lipoprotein metabolism in healthy men.

Authors:  André J Tremblay; Benoît Lamarche; Valérie Guay; Amélie Charest; Valéry Lemelin; Patrick Couture
Journal:  Am J Clin Nutr       Date:  2013-05-29       Impact factor: 7.045

8.  Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

Authors:  T Vilsbøll; T Krarup; J Sonne; S Madsbad; A Vølund; A G Juul; J J Holst
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

9.  Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction.

Authors:  Mehran Haidari; Nathalie Leung; Farhana Mahbub; Kristine D Uffelman; Rita Kohen-Avramoglu; Gary F Lewis; Khosrow Adeli
Journal:  J Biol Chem       Date:  2002-06-17       Impact factor: 5.157

10.  Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL.

Authors:  Nirupa R Matthan; Ann Giovanni; Ernst J Schaefer; B Greg Brown; Alice H Lichtenstein
Journal:  J Lipid Res       Date:  2003-02-01       Impact factor: 5.922

View more
  12 in total

Review 1.  Intestinal lipid absorption and lipoprotein formation.

Authors:  M Mahmood Hussain
Journal:  Curr Opin Lipidol       Date:  2014-06       Impact factor: 4.776

2.  Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance.

Authors:  Jean-Philippe Drouin-Chartier; André J Tremblay; Jean-Charles Hogue; Valéry Lemelin; Benoît Lamarche; Patrick Couture
Journal:  J Lipid Res       Date:  2018-06-26       Impact factor: 5.922

Review 3.  Intestinal lipid absorption and transport in type 2 diabetes.

Authors:  Bruno Vergès
Journal:  Diabetologia       Date:  2022-07-30       Impact factor: 10.460

4.  Substitution of dietary ω-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance: a randomized controlled trial.

Authors:  Jean-Philippe Drouin-Chartier; André J Tremblay; Marie-Claude Lépine; Valéry Lemelin; Benoît Lamarche; Patrick Couture
Journal:  Am J Clin Nutr       Date:  2018-01-01       Impact factor: 7.045

5.  Altered intestinal functions and increased local inflammation in insulin-resistant obese subjects: a gene-expression profile analysis.

Authors:  Alain Veilleux; Sylvain Mayeur; Jean-Christophe Bérubé; Jean-François Beaulieu; Eric Tremblay; Frédéric-Simon Hould; Yohan Bossé; Denis Richard; Emile Levy
Journal:  BMC Gastroenterol       Date:  2015-09-16       Impact factor: 3.067

6.  Evaluation of iTRAQ and SWATH-MS for the Quantification of Proteins Associated with Insulin Resistance in Human Duodenal Biopsy Samples.

Authors:  Sylvie Bourassa; Frédéric Fournier; Benjamin Nehmé; Isabelle Kelly; André Tremblay; Valéry Lemelin; Benoit Lamarche; Patrick Couture; Arnaud Droit
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

7.  Deregulated Lipid Sensing by Intestinal CD36 in Diet-Induced Hyperinsulinemic Obese Mouse Model.

Authors:  Marjorie Buttet; Hélène Poirier; Véronique Traynard; Kévin Gaire; Thi Thu Trang Tran; Sinju Sundaresan; Philippe Besnard; Nada A Abumrad; Isabelle Niot
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

8.  Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects.

Authors:  Kentaro Sakamoto; Mitsunobu Kawamura; Takayuki Watanabe; Keiko Ashidate; Takahide Kohro; Akira Tanaka; Yasumichi Mori; Motoki Tagami; Tsutomu Hirano; Tsutomu Yamazaki; Teruo Shiba
Journal:  Lipids Health Dis       Date:  2017-06-24       Impact factor: 3.876

9.  Oral Glucose Mobilizes Triglyceride Stores From the Human Intestine.

Authors:  Changting Xiao; Priska Stahel; Alicia L Carreiro; Yu-Han Hung; Satya Dash; Ian Bookman; Kimberly K Buhman; Gary F Lewis
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-10-12

Review 10.  Role of the Gut in Diabetic Dyslipidemia.

Authors:  Priska Stahel; Changting Xiao; Avital Nahmias; Gary F Lewis
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-13       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.